Takuro Okada
Tokyo Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Takuro Okada.
Oncotarget | 2017
Soichiro Takase; Satoshi Kano; Yuichiro Tada; Daisuke Kawakita; Tomotaka Shimura; Hideaki Hirai; Kiyoaki Tsukahara; Akira Shimizu; Yorihisa Imanishi; Hiroyuki Ozawa; Kenji Okami; Yuichiro Sato; Yukiko Sato; Chihiro Fushimi; Takuro Okada; Hiroki Sato; Kuninori Otsuka; Yoshihiro Watanabe; Akihiro Sakai; Koji Ebisumoto; Takafumi Togashi; Yushi Ueki; Hisayuki Ota; Toyoyuki Hanazawa; Hideaki Chazono; Robert Yoshiyuki Osamura; Toshitaka Nagao
Salivary duct carcinoma (SDC) is an uncommon, aggressive malignant neoplasm histologically resembling high-grade mammary ductal carcinoma. SDC can arise de novo or ex pleomorphic adenoma. To clarify the correlation of biomarker immunoprofile with clinicopathological findings and clinical outcome of SDC, we conducted immunohistochemistry for EGFR, HER2, HER3, AR, CK5/6, p53, and Ki-67, along with HER2 fluorescence in situ hybridization in 151 SDCs. SDCs ex pleomorphic adenoma more commonly overexpressed EGFR, HER2, HER3, and Ki-67 than de novo SDCs (P = 0.015, < 0.001, 0.045, and 0.02, respectively). In multivariate analysis, AR− and CK5/6+ were associated with shorter progression-free survival (P = 0.027 and 0.004, respectively). Moreover, patients with p53-extreme negative/positive demonstrated poorer overall survival (P = 0.007). On assessing the revised classification by the combination of biomarker expression, the percentages of each subtype were as follows: ‘apocrine A’ (AR+/HER2−/Ki-67-low) (24%), ‘apocrine B’ (AR+/HER2−/Ki-67-high) (18%), ‘apocrine HER2’ (AR+/HER2+) (35%), ‘HER2-enriched’ (AR−/HER2+) (12%), and ‘double negative’ (AR−/HER2−) (11%). ‘Double negative’ was further subclassified into ‘basal-like’ (EGFR and/or CK5/6+) (7%) and ‘unclassified’ (3%). Consequently, patients with ‘apocrine A’ showed a better progression-free survival than those with any other subtypes. Our revised immunoprofiling classification was valuable for predicting the survival and might be useful in personalized therapy for patients with SDC.
Oncotarget | 2017
Daisuke Kawakita; Yuichiro Tada; Yorihisa Imanishi; Shintaro Beppu; Kiyoaki Tsukahara; Satoshi Kano; Hiroyuki Ozawa; Kenji Okami; Yuichiro Sato; Akira Shimizu; Yukiko Sato; Chihiro Fushimi; Soichiro Takase; Takuro Okada; Hiroki Sato; Kuninori Otsuka; Yoshihiro Watanabe; Akihiro Sakai; Koji Ebisumoto; Takafumi Togashi; Yushi Ueki; Hisayuki Ota; Tomotaka Shimura; Toyoyuki Hanazawa; Shingo Murakami; Toshitaka Nagao
The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models.High mGPS (≥1) was significantly associated with worse survival (3-year overall survival (OS): 16.7% vs 66.1%, p-value=0.003; 3-year progression-free survival (PFS): 0.0% vs 27.9%, p-value<0.001). Additionally, high C-reactive protein (CRP) (≥0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1% vs 68.2%, p-value=0.001; 3-year PFS: 7.1% vs 31.1%, p-value<0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (≥2.5) with OS (HR 1.80; 95% confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients.
Oncotarget | 2018
Tomotaka Shimura; Yuichiro Tada; Hideaki Hirai; Daisuke Kawakita; Satoshi Kano; Kiyoaki Tsukahara; Akira Shimizu; Soichiro Takase; Yorihisa Imanishi; Hiroyuki Ozawa; Kenji Okami; Yuichiro Sato; Yukiko Sato; Chihiro Fushimi; Hideaki Takahashi; Takuro Okada; Hiroki Sato; Kuninori Otsuka; Yoshihiro Watanabe; Akihiro Sakai; Koji Ebisumoto; Takafumi Togashi; Yushi Ueki; Hisayuki Ota; Mizuo Ando; Shinji Kohsaka; Toyoyuki Hanazawa; Hideaki Chazono; Yoshiyuki Kadokura; Hitome Kobayashi
The molecular characteristics of therapeutically-relevant targets and their clinicopathological implications in salivary duct carcinomas (SDCs) are poorly understood. We investigated the gene alterations and the immunoexpression of crucial oncogenic molecules in 151 SDCs. The mutation rates that were identified, in order of frequency, were as follows: TP53, 68%; PIK3CA, 18%; H-RAS, 16%; BRAF, 4%; and AKT1, 1.5%. PIK3CA/H-RAS/BRAF mutations were more common in de novo SDC than in SDC ex-pleomorphic adenoma. Furthermore, these mutations were mutually exclusive for HER2 overexpression/amplification. TP53 mutations were frequently detected in cases with the aberrant p53 expression, and TP53 missense and truncating mutations were associated with p53-extreme positivity and negativity, respectively. DISH analysis revealed no cases of EGFR amplification. The rates of PI3K, p-Akt, and p-mTOR positivity were 34%, 22%, and 66%, respectively; PTEN loss was observed in 47% of the cases. These expressions were correlated according to the signaling axis. Cases with PI3K negativity and PTEN loss appeared to show a lower expression of androgen receptor. In the multivariate analysis, patients with SDC harboring TP53 truncating mutations showed shorter progression-free survival. Conversely, p-Akt positivity was associated with a favorable outcome. This study might provide information that leads to advances in personized therapy for SDC.
Histopathology | 2018
Makoto Urano; Hideaki Hirai; Yuichiro Tada; Daisuke Kawakita; Tomotaka Shimura; Kiyoaki Tsukahara; Satoshi Kano; Hiroyuki Ozawa; Kenji Okami; Yuichiro Sato; Chihiro Fushimi; Akira Shimizu; Soichiro Takase; Takuro Okada; Hiroki Sato; Yorihisa Imanishi; Kuninori Otsuka; Yoshihiro Watanabe; Akihiro Sakai; Koji Ebisumoto; Takafumi Togashi; Yushi Ueki; Hisayuki Ota; Yukiko Sato; Natsuki Saigusa; Masato Nakaguro; Toyoyuki Hanazawa; Toshitaka Nagao
Salivary duct carcinoma (SDC) is an uncommon, aggressive tumour that, histologically, resembles high‐grade mammary ductal carcinoma, and is characterised by the expression of androgen receptor (AR). The androgen signalling pathway, a potential therapeutic target, can be regulated by FOXA1. This study aimed to evaluate the clinicopathological implications of FOXA1 in SDC.
Acta Oto-laryngologica | 2018
Chihiro Kanno; Tatsuo Masubuchi; Yuichiro Tada; Chihiro Fushimi; Takashi Matsuki; Hideaki Takahashi; Takuro Okada; Toru Inomata; Masashi Sasaki; Kazutomo Niwa; Toshimasa Machida; Kouki Miura
Abstract Objective: Currently, many studies are being performed that focus on the efficacy and safety of the vessel sealing system (VSS) in various fields of surgery. However, in the field of oral cancer surgery, the efficacy and safety of VSS use have not been clarified. Methods: One hundred and fifty-one patients underwent oral cancer resection and reconstructive surgery. They were divided into two groups: Ligasure vessel sealing system (LVSS) group and conventional surgery (CS) as control. Intra-operative blood loss, operating time, and incidence of post-operative complications and recurrence were analyzed. Results: LVSS use significantly reduced intra-operative blood loss. The operating time was shortened only in mandibular gingiva cancer surgery. There were no differences between the two groups with regard to the incidence of post-operative complications and recurrence. Conclusions: LVSS use was found to be effective and proved to be efficient and safe, and may be useful in oral cancer surgery.
International Journal of Clinical Oncology | 2017
Rio Kojima; Kiyoaki Tsukahara; Ray Motohashi; Takuro Okada; Masanori Yatomi; Yasuaki Katsube; Atsuo Takeda; Ayumi Agata; Yasuo Ogawa
Nihon Kikan Shokudoka Gakkai Kaiho | 2016
Takuro Okada; Yasuo Ogawa; Nobutoshi Funato; Mamoru Suzuki
Nihon Kikan Shokudoka Gakkai Kaiho | 2010
Kazuhiro Nakamura; Kiyoaki Tsukahara; Tomoyuki Yoshida; Taro Inagaki; Masaaki Shimizu; Fumimasa Toyomura; Takuro Okada; Mamoru Suzuki
Nihon Kikan Shokudoka Gakkai Kaiho | 2017
Hideki Tanaka; Kiyoaki Tsukahara; Rei Motohashi; Takuro Okada; Masanori Yatomi; Atsuo Takeda; Rio Kojima; Tomoo Ogawa
Journal of Japan Society for Head and Neck Surgery | 2017
Isaku Okamoto; Kiyoaki Tsukahara; Hiroki Sato; Rei Motohashi; Takahito Kondo; Takuro Okada; Akira Shimizu